ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

ABSTRACT: The last few decades have witnessed a silent revolution in the war against NSCLC, thanks to the discovery of "oncogenic drivers" and the subsequent development of targeted therapies. The discovery of the EML4-ALK fusion gene in a subgroup of patients with NSCLC and the subsequent clinical development of crizotinib has been an amazing success story in lung cancer translational-research, and its accelerated approval [only 4 years from the discovery of ALK rearrangement in NSCLC to the approval by the Food and Drug Administration (FDA)] marked the beginning of the new decade of targeted therapy. However, common to all targeted therapies, despite an initial benefit, patients inevitably experience tumor progression, due to the development of resistance. Several molecular mechanisms are responsi

SUBMITTER: Rolfo C 

PROVIDER: S-EPMC4367701 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature